DANIPHARM A/S: Financial statements 2024
CVR: 12335040
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
DANIPHARM A/S (CVR 12335040) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 34,065,329 and a net result of DKK 5,113,647 compared with DKK 5,390,779 the year before. That is a decrease of 3.1% compared with the year before. Equity in the 2024 report amounted to DKK 46,563,645. The solvency ratio was 48.7%. The company had 26 employees in the financial year.
- Gross Profit
- DKK 34,065,329
- Profit/Loss
- DKK 5,113,647
- Equity
- DKK 46,563,645
- Total Assets
- DKK 95,569,386
- Employees
- 26
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 34.1 mio. | 5.1 mio. | 46.6 mio. | 26 |
| 2023 | - | 35.2 mio. | 5.4 mio. | 41.4 mio. | 28 |
| 2022 | - | 34.9 mio. | 8.2 mio. | 36.1 mio. | 26 |
| 2021 | - | 29.4 mio. | 2.9 mio. | 29.9 mio. | 25 |
| 2020 | 91.6 mio. | 31.6 mio. | 5.8 mio. | 26.9 mio. | 22 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout DANIPHARM A/S
DANIPHARM A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1988. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Peter Rørvig. The board consists of Niels Ulrik Heine (chair), Helle Rørvig and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. Equity in the 2025 report amounted to DKK 60,280,949.